TABLE 3.
Treatmenta | Reduction of ferricytochrome c (nmol of O2−/106 neutrophils)b |
---|---|
Experiment 1 | |
Medium control | 1.8 ± 0.2 |
PMA | 21.1 ± 3.4∗ |
MDC | 4.5 ± 0.4 |
MDC + PMA | 18.7 ± 0.3∗ |
MDC + A. phagocytophila + PMA | 4.7 ± 0.3 |
Neomycin | 2.3 ± 0.4 |
Neomycin + PMA | 14.7 ± 0.2∗ |
Neomycin + A. phagocytophila + PMA | 2.8 ± 0.5 |
Genistein | 3.7 ± 2.2 |
Genistein + PMA | 15.4 ± 1.2∗ |
Genistein + A. phagocytophila + PMA | 4 ± 3.1 |
H89 | 3.8 ± 1.4 |
H89 + PMA | 16.4 ± 0.3∗ |
H89 + A. phagocytophila + PMA | 2.4 ± 0.1 |
Experiment 2 | |
Medium control | 0.4 ± 0.6 |
PMA | 8.5 ± 0.6∗ |
A. phagocytophila | 1.7 ± 0.2 |
A. phagocytophila + PMA | 1.9 ± 1.0 |
PL1 + PMA | 6.3 ± 0.6∗ |
A. phagocytophila + PL1 + PMA | 1.8 ± 0.5 |
Neutrophils were pretreated with or without reagents (250 μM MDC, 10 μM neomycin, 50 μM genistein, 10 μM H89, or 2.5 pg of anti-PSGL-1) for 30 min prior to addition of A. phagocytophila and PMA stimulation. Reagents were present throughout assays.
Mean ± standard deviation (n = 3). Results are representative of more than three independent experiments. ∗, P < 0.01 compared to neutrophil-alone (no PMA) control (Student's t test).